An interventional study of Atosiban and Placebo Control in Infertility, sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi. Recruiting at 1 site in China. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Infertility with a site in China — 38 open to participants now, 41 under way, 5 of them phase 3. Infertility · China.
Among the 139 studies in Infertility with a site in China, this one is the 23rd largest by planned enrollment of the 107 interventional ones that give a count, is one of 14 that started in 2025, is one of 65 with no phase, reaches primary completion later than 19 of the 40 other live ones, and was the 125th registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →38 of the 139 studies in Infertility with a site in China are open now. Recruiting first, the newest first:
Peking University People's Hospital · Sites in China
Ages 20–40 · Women only
Changchun GeneScience Pharmaceutical Co., Ltd. · Sites in China
Ages 36–39 · Women only
Li Li · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Tang-Du Hospital · Sites in China
Ages 20–45 · Women only
Li-jun Ding · Sites in China
Ages 18–39 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 20 Years to 40 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 3 15 · Phase 4 14
First in 2003; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 792 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 248 across the 107 interventional studies, 550 across the 32 observational. Of the 56 that completed or were terminated, 4 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 139 have an industry lead sponsor. The 10 most frequent:
Northwest Women's and Children's Hospital, Xi'an, Shaanxi is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Northwest Women's and Children's Hospital, Xi'an, Shaanxi has 3 studies filed under Infertility — fewer than ten, so there is no comparison to draw.
12 of the studies in Infertility with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06571214Nanjing UniversityPotential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment | 2026-12-30 |
| NCT06020924Wenwen WangThe Effects of Uterine Fibroids on Pregnancy in Women | 2026-12-31 |
| NCT07696351Li-jun DingUltra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis | 2026-12-31 |
| NCT07050537The First Affiliated Hospital with Nanjing Medical UniversityA Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology | 2027-03-31 |
| NCT07533630Reproductive & Genetic Hospital of CITIC-XiangyaProspective International Multi-center Clinical Trial of PGT-A Upgrade | 2027-06 |
Add all 12 to your calendar (.ics) → With an account.
Among the 139 studies in Infertility with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the efficacy of atosiban in patients with previous pregnancy failure and abnormal uterine contractions during the peri-embryo transfer period in assisted reproductive technology. The main questions it aims to answer are:
Researchers will compare atosiban with placebo (a similar substance containing no active medication) to determine whether atosiban is effective in improving live birth rates from single blastocyst transfer cycles (fresh or frozen-thawed embryo transfer) in patients with a history of implantation failure and abnormal uterine contractions.
Participants/eligibility criteria
Infertile women who fulfill all of the following inclusion criteria, based on the results and findings of the Atosiban 1 study are eligible for participation:
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants allocated to the Atosiban group will be administered Atosiban
Drug: Atosiban
Participants allocated to the placebo group will receive saline infusions.
Drug: Placebo Control
Participants allocated to the Atosiban group will be administered Atosiban (37.5 mg/5 mL, Tractocile®, Ferring Pharma, Geneva, Switzerland) as an intravenous (IV) bolus of 6·75 mg/0.9 mL in 1 minute at 30 minutes prior to the ET procedure, followed by an IV infusion at a rate of 18 mg/h for 1 hour; after 1 hour, the dose of Atosiban will be reduced to 6 mg/h, with a total dose of 37.5 mg.
Participants allocated to the placebo group will receive identical-looking saline infusions for the same duration.
Live birth
Live birth is defined as the delivery of at least one newborn who exhibits any sign of life.
Time frame: After 24 weeks of gestation
Biochemical pregnancy
Biochemical pregnancy is defined as serum beta-human chorionic gonadotropin β-hCG\> 10 IU/L 12 days after blastocyst transfer.
Time frame: 12 days after blastocyst transfer
Clinical pregnancy
Clinical pregnancy is defined as observed gestational sac or definitive clinical signs of pregnancy observed at ultrasonography (including clinically documented ectopic pregnancy)
Time frame: 6-8 weeks after blastocyst transfer.
Ongoing pregnancy
Ongoing pregnancy is defined as the presence of a gestational sac and fetal heartbeat after 12 weeks of gestation.
Time frame: After 12 weeks of gestation
Miscarriage
Miscarriage is defined as spontaneous loss of an intrauterine pregnancy prior to 20 completed weeks of gestational age.
Time frame: before 20 weeks of gestation.
Stillbirth
Stillbirth is defined as the death of a fetus prior to the complete expulsion or extraction from its mother after 20 completed weeks of gestational age including deaths during labor.
Time frame: after 20 weeks of gestation
Ectopic pregnancy
Ectopic pregnancy is defined as a pregnancy outside the uterine cavity, diagnosed by ultrasound, surgical visualization, or histopathology.
Time frame: After 4 to 6 weeks of embryo transfer
Multiple pregnancy
Multiple pregnancy is defined as a pregnancy with two or more gestational sacs or positive heart beats at 7 weeks of gestation.
Time frame: 7 weeks of gestation
Gestational diabetes mellitus
Newly diagnosed diabetes or gestational diabetes at 28 weeks of pregnancy confirmed by 75 g oral glucose tolerance test.
Time frame: At 28 weeks of pregnancy
hypertensive disorders of pregnancy
Time frame: From 20 weeks of gestation up to at birth
preterm birth
Delivery of a fetus at less than 37 and more than 28 weeks gestational age
Time frame: At birth
low birth weight
Weight of baby born \< 2500 g
Time frame: At birth
Very low birth weight
Weight of baby born \< 1500 g
Time frame: At birth
high birth weight
Weight of baby born \> 4000 g
Time frame: at birth
large for gestational age
large for gestational age is defined as birth weight greater than 90th percentile for gestation, based on standardised ethnicity-based charts
Time frame: at birth
small for gestational age
small for gestational age is defined as less than 10th percentile for gestational age at delivery based on standardised ethnicity-based charts.
Time frame: at birth
Early neonatal death
Early neonatal death refers to death of a live born baby within 7days of birth
Time frame: within 7days of birth
Congenital anomaly
Any congenital anomalies detected in baby born
Time frame: Birth to first year of life
Plan to share: No
Started Dec 2025 (actual). Primary completion is estimated for Jun 2027, 18 months after the start.
Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 18 months is below that.
Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atosiban
Northwest Women's and Children's Hospital, Xi'an, Shaanxi